Nuplazid Capsule
NDC Package 63090-340-30

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Nuplazid (pimavanserin tartrate) capsules is pimavanserin is used to treat the symptoms of a certain mental/mood disorder (psychosis) that might occur with Parkinson's disease. This formulation utilizes a capsule delivery system. Marketed by Acadia Pharmaceuticals Inc., this product is identified by NDC 63090-340 and is authorized under FDA application NDA210793.

Identification & Billing

NDC Package Code
63090-340-30
Package Description
30 CAPSULE in 1 BOTTLE, PLASTIC
Product Code
63090-340
11-Digit Billing Format
63090034030
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
30 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Nuplazid
Non-Proprietary Name
Pimavanserin Tartrate
Substance Name
Pimavanserin Tartrate
Dosage Form
Capsule - A solid oral dosage form consisting of a shell and a filling. The shell is composed of a single sealed enclosure, or two halves that fit together and which are sometimes sealed with a band. Capsule shells may be made from gelatin, starch, or cellulose, or other suitable materials, may be soft or hard, and are filled with solid or liquid ingredients that can be poured or squeezed.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
PIMAVANSERIN TARTRATE 34 mg/1
Pharmacologic Class
Atypical Antipsychotic - [EPC] (Established Pharmacologic Class)
Usage Information
Pimavanserin is used to treat the symptoms of a certain mental/mood disorder (psychosis) that might occur with Parkinson's disease. It helps lessen symptoms such as seeing or hearing things that are not there (hallucinations) and false beliefs (delusions). Pimavanserin belongs to a class of drugs known as atypical antipsychotics, though it works differently from most other drugs in this class.

Regulatory & Marketing

Labeler Name
Acadia Pharmaceuticals Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA210793
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
06-28-2018
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 63090-340-30 identifies a specific commercial package of 30 capsule in 1 bottle, plastic of Nuplazid, a human prescription drug labeled by Acadia Pharmaceuticals Inc.. This capsule is formulated for oral use and contains pimavanserin tartrate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Acadia Pharmaceuticals Inc. on June 28, 2018. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

Pimavanserin is used to treat the symptoms of a certain mental/mood disorder (psychosis) that might occur with Parkinson's disease. It helps lessen symptoms such as seeing or hearing things that are not there (hallucinations) and false beliefs (delusions). Pimavanserin belongs to a class of drugs known as atypical antipsychotics, though it works differently from most other drugs in this class.

How is this Acadia Pharmaceuticals Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 63090034030. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
63090-340-30
11-Digit CMS (5-4-2)
63090-0340-30

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.